Bernard Escudier and Viktor Grünwald take us through the metastatic renal cell carcinoma studies that caught their attention at the 2020 Genitourinary Cancers Symposium, including long-term data from the CheckMate 214 trial and studies of novel agents such as the HIF-2α inhibitor MK-6482 and sitravatinib. This independent video was supported by an educational grant from Pfizer and Merck KGaA.

Axel Merseburger takes us through the studies that caught his attention at ASCO GU 2020, including the NIMBUS trial and first-in-human study of the HIF-2α inhibitor MK-6482 (3:24).

Axel Merseburger and Laurence Albigès discuss the treatment options for patients with advanced renal cell carcinoma and highlight some of the novel data presented at the 2020 Genitourinary Cancers Symposium that may affect practice in the future. This independent video was supported by an educational grant from Pfizer and Merck KGaA.

The findings were subsequently published in The New England Journal of Medicine  in 2020 and led to the 2020 US FDA approval  of maintenance avelumab in this patient population at a recommended dose of 800 mg every 2 weeks.

Jonathan Rosenberg video asco CTA At the time of analysis, the median duration of response was not reached, and 53.7% of participants had a response lasting at least 1 year.

Daniel Kwon (University of California, San Francisco, USA) and co-investigators therefore queried the University of California Health COVID Research Data Set – a centralized database for five academic medical centers and 12 affiliated hospitals – to identify 5211 men with prostate cancer who underwent SARS-CoV-2 testing between February and December 2020.

ASCO GU 2020: Petros Grivas explains why the story of PARP inhibitors in advanced urothelial carcinoma continues despite the negative results of the

ASCO GU 2020: Shilpa Gupta gives the top-line results of the BLASST-1 trial of nivolumab added to chemotherapy in muscle-invasive bladder cancer

ASCO expert Robert Dreicer shares his views on the updates from the CARD, TITAN, and STOMP prostate cancer trials presented at ASCO GU 2020 (3:07). Read more about the STOMP trial and the CARD trial

A phase 2 trial update for hypoxia-inducible factor-2α inhibitor MK-6482 in patients with treatment-naïve renal cell carcinoma associated with von Hippel-Lindau disease has been presented at the ESMO Virtual Congress 2020.

The efficacy and safety results were presented at the virtual 2020 ASCO Annual Meeting by Elizabeth Plimack, from Fox Chase Cancer Center in Philadelphia, Pennsylvania, USA, and follow on from the interim analysis findings after a minimum of 7 months of follow-up that were presented at ASCO GU 2019.

Commenting on the safety data, Beer said that “potential differences in toxicity merit further evaluation in the context of a direct comparison between these agents,” and stressed that attention to toxicity could be key in selecting the appropriate agent for patients. medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group 2020 ASCO Annual Meeting; 29–31 May (Abstract 5514) 2020 ASCO Annual Meeting; 29–31 May (Abstract 5515) 2020 ASCO Annual Meeting; 29–31 May (Abstract 5516) N Engl J Med 2020; 382 : 2197–2206

Results from two studies presented at the virtual 2020 ASCO Annual Meeting suggest that the strategy of using single-agent nivolumab followed by response-adaptive or salvage add-on ipilimumab cannot be recommended for patients with advanced renal cell carcinoma. This independent news story was supported by an educational grant from Pfizer and Merck KGa

He added: “The FRACTION-RCC trial offers, overall, a novel, efficient strategy for assessing [immuno-oncology] therapies to provide new treatment options for advanced RCC patients with high unmet medical needs.” medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group This independent news story was supported by an educational grant from Pfizer and Merck KGaA 2020 ASCO Annual Meeting; 29–31 May

He added: “The CONDOR trial coupled with the OSPREY study has now established the performance characteristics of [ 18 F-DCFPyL] across the full spectrum of prostate cancer.” medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group 2020 ASCO Annual Meeting; 29–31 May

Axel Merseburger takes us through his picks of the genitourinary cancers track of the virtual 2020 ASCO Annual Meeting, including the JAVELIN Bladder 100 and KEYNOTE-426 trials (10:28).

The interim analysis of the phase 2 expansion cohort of the Study 111/KEYNOTE-146 trial was presented at the virtual 2020 ASCO Annual Meeting by Chung-Han Lee, from Memorial Sloan Kettering Cancer Center in New York, USA.

The findings of this cohort of the phase 1b trial were presented in a poster discussion session of the virtual 2020 ASCO Annual Meeting by Sumanta Pal (City of Hope Comprehensive Cancer Center, Duarte, California, USA) on behalf of his co-authors.